Conference Coverage

Two-thirds of U.S. teens fail to get needed vaccines


 

FROM IDWEEK 2020

Schedule next dose at first visit

One thing her department has found successful in HPV completion is scheduling the second dose while the teen is in the office for the first dose.

“Also, you have to recommend it just as strongly for boys as you do for girls, because oropharyngeal cancer is like an epidemic right now for men, and HPV-related oropharyngeal cancer is on an exponential rise,” Dr. Fricchione said.

According to the CDC, HPV is thought to cause 70% of oropharyngeal cancers in the United States.

Equipping providers with statistics on the effectiveness of HPV vaccination in preventing cancer can take away the uneasiness in talking about sexual transmission.

“That really seems to help them give a strong recommendation. It puts them in a data-driven position to talk about the vaccine,” she said. “Once you put that data in front of the providers, they’re floored.”

Research was funded by GlaxoSmithKline. Dr. Poston is employed by GlaxoSmithKline. Dr. Fricchione disclosed no relevant financial relationships.

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

Dangers behind antimaskers and antivaxxers: How to combat both
MDedge Infectious Disease
Three major COVID vaccine developers release detailed trial protocols
MDedge Infectious Disease
J&J’s one-shot COVID-19 vaccine advances to phase 3 testing
MDedge Infectious Disease
Shingrix effective in older adults with preexisting immune-mediated disorders
MDedge Infectious Disease
COVID-19 may discourage pediatric flu vaccination
MDedge Infectious Disease
COVID-19 vaccine hesitancy ‘somewhat understandable,’ expert says
MDedge Infectious Disease
HPV vaccination remains below Healthy People goals despite increases
MDedge Infectious Disease
Flu vaccine significantly cuts pediatric hospitalizations
MDedge Infectious Disease
Fauci: Cautious optimism for COVID-19 vaccine by end of 2020
MDedge Infectious Disease
Survey: Acceptance of COVID-19 vaccine dips below 50%
MDedge Infectious Disease